Relypsa (Relypsa) Scaled Net Operating Assets : 0.05 (As of Jun. 2016)

View and export this data going back to 2013. Start your Free Trial

What is Relypsa Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Relypsa's operating assets for the quarter that ended in Jun. 2016 was $63.85 Mil. Relypsa's operating liabilities for the quarter that ended in Jun. 2016 was $52.08 Mil. Relypsa's Total Assets for the quarter that ended in Mar. 2016 was $261.38 Mil. Therefore, Relypsa's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2016 was 0.05.

Relypsa Scaled Net Operating Assets Historical Data

The historical data trend for Relypsa's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa Scaled Net Operating Assets Chart

Relypsa Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Scaled Net Operating Assets

-3.74

-6.62

-0.10

-0.01

-0.26

Relypsa Quarterly Data
	Dec11	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Scaled Net Operating Assets	Get a 7-Day Free Trial												-0.03	-0.14	-0.13	-0.02	0.05

Competitive Comparison of Relypsa's Scaled Net Operating Assets

For the Biotechnology subindustry, Relypsa's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relypsa's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Relypsa's Scaled Net Operating Assets falls into.

Relypsa Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Relypsa's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2015 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2015 )
=	(Operating Assets (A: Dec. 2015 )	-	Operating Liabilities (A: Dec. 2015 ))	/	Total Assets (A: Dec. 2014 )
=	(37.612	-	77.562)	/	151.839
=	-0.26

where

	Operating Assets		(A: Dec. 2015 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	278.328	-	240.716
=	37.612

	Operating Liabilities		(A: Dec. 2015 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	93.455	-	15.592	-	0.301
=	77.562

Relypsa's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2016 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2016 )
=	(Operating Assets (Q: Jun. 2016 )	-	Operating Liabilities (Q: Jun. 2016 ))	/	Total Assets (Q: Mar. 2016 )
=	(63.851	-	52.076)	/	261.384
=	0.05

where

	Operating Assets		(Q: Jun. 2016 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	321.577	-	257.726
=	63.851

	Operating Liabilities		(Q: Jun. 2016 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	210.657	-	158.581	-	0
=	52.076

Relypsa Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Relypsa's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Relypsa (Relypsa) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.relypsa.com

Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Executives

Ronald A. Krasnow	officer: See Remarks	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball	officer: Chief Financial Officer & SVP	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J	director	33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl	officer: SVP, Chief Technology Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland	officer: SVP & Chief Commercial Officer	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley	director	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi • 10-26-2015